NRx Pharmaceuticals Valuation
Is NRXP undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of NRXP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate NRXP's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate NRXP's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for NRXP?
Other financial metrics that can be useful for relative valuation.
| What is NRXP's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | US$28.70m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | -1.2x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does NRXP's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3.4x | ||
RGC Regencell Bioscience Holdings | 6x | n/a | US$67.9m |
CALC CalciMedica | 5.3x | 20.3% | US$43.1m |
IXHL Incannex Healthcare | 2x | n/a | US$37.8m |
SHWZ Medicine Man Technologies | 0.4x | n/a | US$54.8m |
NRXP NRx Pharmaceuticals | n/a | n/a | US$28.7m |
Price-To-Book vs Peers: NRXP has negative equity and a Price-To-Book Ratio (-2.5x) compared to the peer average (3.4x).
Price to Earnings Ratio vs Industry
How does NRXP's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price-To-Book vs Industry: NRXP has negative equity and a Price-To-Book Ratio (-2.5x) compared to the US Pharmaceuticals industry average (1.9x).
Price to Book Ratio vs Fair Ratio
What is NRXP's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | -2.5x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate NRXP's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$3.04 | US$37.50 +1,133.6% | 46.7% | US$55.00 | US$20.00 | n/a | 2 |
| Apr ’25 | US$5.25 | US$37.50 +614.3% | 46.7% | US$55.00 | US$20.00 | n/a | 2 |
| Mar ’25 | US$4.38 | US$37.50 +756.0% | 46.7% | US$55.00 | US$20.00 | n/a | 2 |
| Feb ’25 | US$3.74 | US$37.50 +902.9% | 46.7% | US$55.00 | US$20.00 | n/a | 2 |
| Jan ’25 | US$4.60 | US$37.50 +715.2% | 46.7% | US$55.00 | US$20.00 | n/a | 2 |
| Dec ’24 | US$3.67 | US$36.25 +887.7% | 44.8% | US$52.50 | US$20.00 | n/a | 2 |
| Nov ’24 | US$3.06 | US$36.25 +1,086.6% | 44.8% | US$52.50 | US$20.00 | n/a | 2 |
| Oct ’24 | US$2.60 | US$36.25 +1,294.2% | 44.8% | US$52.50 | US$20.00 | n/a | 2 |
| Sep ’24 | US$2.98 | US$35.00 +1,074.5% | 42.9% | US$50.00 | US$20.00 | n/a | 2 |
| Aug ’24 | US$3.99 | US$35.00 +776.5% | 42.9% | US$50.00 | US$20.00 | n/a | 2 |
| Jul ’24 | US$4.84 | US$35.00 +623.9% | 42.9% | US$50.00 | US$20.00 | n/a | 2 |
| Jun ’24 | US$7.30 | US$35.00 +379.5% | 42.9% | US$50.00 | US$20.00 | n/a | 2 |
| May ’24 | US$5.71 | US$33.75 +491.0% | 40.7% | US$47.50 | US$20.00 | n/a | 2 |
| Apr ’24 | US$6.59 | US$32.50 +393.1% | 38.5% | US$45.00 | US$20.00 | US$5.25 | 2 |
| Mar ’24 | US$9.30 | US$32.50 +249.5% | 38.5% | US$45.00 | US$20.00 | US$4.38 | 2 |
| Feb ’24 | US$11.80 | US$32.50 +175.4% | 38.5% | US$45.00 | US$20.00 | US$3.74 | 2 |
| Jan ’24 | US$11.10 | US$32.50 +192.8% | 38.5% | US$45.00 | US$20.00 | US$4.60 | 2 |
| Dec ’23 | US$14.80 | US$32.50 +119.6% | 38.5% | US$45.00 | US$20.00 | US$3.67 | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.